Biotech & Drug DiscoveryKONEX 2961601 approvals6 trials

ProGen, Co,, LTD.

Official website

KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1998 and listed on KONEX in 2023, ProGen is a biotech venture built on its multi-target fusion protein platform NTIG®. Flagship candidate PG-102 for obesity/diabetes is in Phase 2, oral drug RPG-102 is in Phase 1; its earlier hyFc® platform was applied to EPO, GH, GLP-1 and IL-7. IgE Trap was licensed to GI Innovation for KRW 18.25 billion, and NTIG® was also licensed to Genexine.

Regulatory approvals

data.go.kr

1 Korean MFDS device approvals · 2013

MFDSreagents for clinical enzymesRevoked2013-12-20
Product approval · Class 2수허 13-3416 호

Clinical trials

data.go.kr

6 MFDS clinical trial authorisations · 2023–2026 (Phase 1 3 · Phase 2 3)

Phase 1PG-1022026-07-13
1 trial site
Phase 2PG-1022026-05-18
Phase 2PG-1022026-02-26
5 trial sites
Phase 2PG-1022024-07-05
13 trial sites
Phase 1PG-1022023-08-07
1 trial site
Phase 1GX-1702023-02-07
3 trial sites

R&D and key agreements

Source: DART corporate disclosure

PG-102 · 비만 및 당뇨질환 · 임상2상 · Flagship program applying the NTIG® multi-target fusion protein platform

RPG-102 · 비만(경구) · 임상1상 · Oral obesity treatment candidate

근육보존제 및 면역질환 치료제 후보물질 · 근육보존/면역질환 · 디스커버리/비임상 · Early-stage pipeline pursued through domestic and overseas open innovation

Not yet compiled: business overview · products. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Boditech Med Inc.1 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

GC Medical Science Corporation1 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

GENEMATRIX INC.1 shared

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

Hanmi Science Co.,Ltd1 shared

KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.

HUMASIS CO., LTD.1 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

OSANG HEALTHCARE CO.,LTD.1 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

PCL. Inc1 shared

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

SD BIOSENSOR INC.1 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

TASCOM Co.,Ltd.1 shared

Develops SimplexTAS, a point-of-care clinical chemistry and immunoassay analyzer for IVD testing.

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Sources and updates

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
AI visibility: Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition